GlassScriptPhysician profile
Robin John Imperial
NPI 1598116931
$1,174.48
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $235 · 2022: $409 · 2023: $442 · 2024: $88.24.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $480 · Education: $49.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $479.99 |
| Education | $49.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $302.32 | 2021-2023 | Adcetris |
| Genentech USA, INC. | $121.79 | 2023 | Columvi, Lunsumio |
| Genzyme Corporation | $121.59 | 2022 | |
| Jazz Pharmaceuticals INC. | $118.15 | 2021 | |
| Janssen Biotech, INC. | $112.18 | 2023 | Rybrevant |
| Pfizer INC. | $88.24 | 2024 | |
| Eisai INC. | $87.48 | 2022 | |
| G1 Therapeutics, INC. | $84.14 | 2022 | |
| Janssen Scientific Affairs, LLC | $59.93 | 2023 | Imbruvica |
| Alexion Pharmaceuticals, INC. | $24.85 | 2023 | |
| Astellas Pharma US INC | $19.08 | 2022 | |
| Amgen INC. | $17.71 | 2022 | |
| Omeros Corporation | $17.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Imperial listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.